Enanta Pharmaceuticals INC 10-Q quarterly reports

Enanta Pharmaceuticals reported a decrease in Q3 2026 revenue to $14.4 million from $18.3 million in the prior year, driven by lower HCV sales, while continuing to invest heavily in its RSV and immunology drug development programs.

Enanta Pharmaceuticals reported a Q2 2026 increase in royalty revenue driven by higher HCV sales, while research and development expenses decreased due to strategic timing of RSV trials.

Enanta Pharmaceuticals reported a significantly reduced net loss in Q1 2026, driven by lower R&D and G&A expenses, while maintaining a strong cash runway into fiscal 2029.

Enanta Pharmaceuticals reported a significant reduction in net loss for the nine months ended June 30, 2025, driven by lower operating expenses, and projects its cash resources will fund operations into fiscal 2028.

Enanta Pharmaceuticals reports a decrease in revenue for Q2 2025 due to lower HCV sales, while highlighting progress in RSV and immunology programs.

Enanta Pharmaceuticals announces its financial results for the quarter ended December 31, 2024, and provides updates on its virology and immunology programs, particularly focusing on RSV.

Enanta Pharmaceuticals reported its financial results for the third quarter of 2024, highlighting ongoing clinical trials and financial position.

Enanta Pharmaceuticals reported its financial results for the second quarter of fiscal year 2024, highlighting ongoing clinical trials for respiratory syncytial virus (RSV) and advancements in its immunology program.

Enanta Pharmaceuticals reported a net loss of $33.4 million for the quarter ended December 31, 2023, with a decrease in royalty revenue and increased R&D spending in certain areas.